Inhibition of neuronal Ca2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices

British Journal of Pharmacology

Volumn 130, Issue 4, 2000, Pages 900-906

  Fink, Klaus ^a   Meder, Wolfgang ^a,b   Dooley, David J ^b   Göthert, Manfred ^a  

^a UNIVERSITY OF BONN   (Germany)

^b PFIZER INC   (United States)

Author keywords

AMPA receptor; Glutamate; Neocortex; NMDA receptor; Noradrenaline; Rat; Synaptosomes; agatoxin IVA; conotoxin GVIA

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR; ASPARTIC ACID; CALCIUM CHANNEL; CALCIUM ION; FURA 2; GABAPENTIN; GLUTAMIC ACID; NORADRENALIN; OMEGA AGATOXIN IVA; OMEGA CONOTOXIN GVIA; POTASSIUM ION;

ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPOLARIZATION; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID SCINTILLATION COUNTING; MALE; NEOCORTEX; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; SYNAPTOSOME;

EID: 0034124987     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703380     Document Type: Article

References (48)

1. BLAUSTEIN, M.P. & GOLDRING, J.M. (1975). Membrane potentials in pinched-off presynaptic nerve terminals, monitored with a fluorescence probe: evidence that synaptosomes have potassium diffusion potentials. J. Physiol. (Lond.), 247, 589-615.
2. 2+ channel toxins. Eur. J. Pharmacol., 238, 383-386.
3. CALABRESI, P., CENTONCE, D., MARFIA, G.A., PISANI, A. & BERNARDI, G. (1999). An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons. Brit. J. Pharmacol., 126, 689-696.
4. CARACENI, A., ZECCA, E., MARTINI, C. & CONNO, F.D. (1999). Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J. Pain Sympt. Man., 17, 441-445.
5. +-evoked glutamate release from slices of rat neocortex by gabapentin. Soc. Neurosci. Abstr., 25, 2254.
6. FAGG, G.E., OLPE, H.R., POZZA, M.F., BAUD, J., STEINMANN, M., SCHMUTZ, M., PORTET, C., BAUMANN, P., THEDINGA, K., BITTIGER, H., ALLGEIER, H., HECKENDORN, R., ANGST, C., BRUNDISH, D. & DINGWALL, J.G. (1990). CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity. Brit. J. Pharmacol., 99, 791-797.
7. FEELY, M. (1999). Drug treatment of epilepsy. Br. Med. J., 318, 106-109.
8. FEUERSTEIN, T.J., DOOLEY, D.J. & SEEGER, W. (1990). Inhibition of norepinephrine and acetylcholine release from human neocortex by omega-conotoxin GVIA. J. Pharmacol. Exp. Ther., 252, 778-785.
9. FINK, K., GÖTHERT, M., MOLDERINGS, G. & SCHLICKER, E. (1989). N-methyl-D-aspartate (NMDA) receptor-mediated stimulation of noradrenaline release, but not release of other neurotransmitters, in the rat brain cortex: receptor location, characterization and desensitization. Naunyn-Schmiedeberg's Arch. Pharmacol., 339, 514-521.
10. FINK, K., MEDER, W., DOOLEY, D.J. & GÖTHERT, M. (1998). Gabapentin-induced inhibition of noradrenaline release in the rat neocortex depends on intact glutamatergic transmission via non-NMDA receptors: relationship to inhibition of calcium flux into glutamatergic nerve terminals. Naunyn-Schmiedeberg's Arch. Pharmacol. Suppl., 358, R685.
11. FINK, K., SCHULTHEISS, R. & GÖTHERT, M. (1992). Stimulation of noradrenaline release in human cerebral cortex mediated by N-methyl-D-aspartate (NMDA) and non-NMDA receptors. Br. J. Pharmacol., 106, 67-72.
12. GAUR, S., NEWCOMB, R., RIVNAY, B., BELL, J.R., YAMASHIRO, D., RAMACHANDRAN, J. & MILJANICH, G.P. (1994). Calcium channel antagonist peptides define several components of transmitter release in the hippocampus. Neuropharmacology, 33, 1211-1219.
13. 2δ subunit of a calcium channel. J. Biol. Chem., 271, 5768-5776.
14. GOA, K.L. & SORKIN, E.M. (1993). Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs, 46, 409-427.
15. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem., 260, 3440-3450.
16. HELMER, C.A. & DOOLEY, D.J. (1998). Differential effects of gabapentin and pregablin on stimulation-evoked catecholamine release from rat brain slices. Soc. Neurosci. Abs., 24, 353.
17. 2+ channels. Neuron, 9, 69-77.
18. 2+ channel diversity. Ann. Rev. Neurosci., 17, 399-418.
19. ISOM, L.L., DE JONGH, K.S. & CATTERAL, W.A. (1994). Auxiliary subunits of voltage-gated ion channels. Neuron, 12, 1183-1194.
20. JIN, S. (1997). AMPA-and kainate-receptors differentially mediate excitatory amino acid-induced dopamine and acetylcholine release from rat striatal slices. Neuropharmacology. 36, 1503-1510.
21. KERR, L.M. & YOSHIKAMI, D. (1984). A venom peptide with novel presynaptic blocking action. Nature, 308, 282-284.
22. 2delta subunit. J. Neurosci., 19, 684-691.
23. LEIDERMAN, D.B. (1994). Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials. Epilepsia, 35, S74-76.
24. LUEBKE, J.L., DUNLAP, K. & TURNER, T.J. (1993). Multiple calcium channel types control glutamatergic synaptic transmission in the hippocampus. Neuron, 11, 895-902.
25. + - and veratridine-induced increases of cytosolic calcium concentration in rat cerebral cortical synaptosomes. Naunyn-Schmiedeberg's Arch. Pharmacol., 356, 797-805.
26. + - and veratridine-induced increase of cytosolic calcium concentration in human cerebral cortical synaptosomes. J. Pharmacol. Exp. Ther., 290, 1126-1131.
27. MINTZ, I.M., VENEMA, V.J., SWIDEREK, K.M., LEE, T.D., BEAN, B.P. & ADAMS, M.E. (1992). P-type calcium channels blocked by the spider toxin ω-Aga-IVA. Nature, 355, 827-829.
28. MULKEY, R.M. & ZUCKER, R.S. (1991). Action potentials must admit calcium to evoke transmitter release. Nature, 350, 153-155.
29. NACHSHEN, D.A. (1985). Regulation of cytosolic calcium concentration in presynaptic nerve endings isolated from rat brain. J. Physiol., 363, 87-101.
30. NIEUWENHUYS, R. (1994). The neocortex. An overview of its evolutionary development, structural organization and synaptology. Anat. Embryol., 190, 307-337.
31. 2+ in rat brain synaptosomes. J. Neurochem., 52, 1837-1842.
32. PANDE, A.C., DAVIDSON, J.R.T., JEFFERSON, J.W., JANNEY, C.A., KATZELNICK, D.J., WEISLER, R.H., GREIST, J.H. & SUTHERLAND, S.M. (1999). Treatment of social phobia with gabapentin: a placebo-controlled study. J. Clin. Psychopharmacol., 19, 341-348.
33. PITTALUGA, A. & RAITERI, M. (1992). N-methyl-D-aspartic acid (NMDA) and non-NMDA receptors regulating hippocampal norepinephrine release. I. Location on axon terminals and pharmacological characterization. J. Pharmacol. Exp. Ther., 260, 232-237.
34. PUGSLEY, T.A., WHETZEL, S.Z., DOOLEY, D.J. (1998). Reduction of 3,4-diaminopyridine-induced biogenic amine synthesis and release in rat brain by gabapentin. Psychopharmacology, 137, 74-80.
35. REIMANN, W. (1983). Inhibition by GABA, baclofen and gabapentin of dopamine release from rabbit caudate nucleus: are there common or different sites of action? Eur. J. Pharmacol., 94, 341-344.
36. ROCK, D.M., KELLY, K.M. & MACDONALD, R.L. (1993). Gabapentin actions on ligand-and voltage-gated responses in cultured rodent neurons. Epilepsy Res., 16, 89-98.
37. SABRIA, J., PASTOR, C., CLOS, M.V., GARCIA, A. & BADIA, A. (1995). Involvement of different types of voltage-sensitive calcium channels in the presynaptic regulation of noradrenaline release in rat brain cortex and hippocampus. J. Neurochem., 64, 2567-2571.
38. SCHLICKER, E., REIMANN, W. & GÖTHERT, M. (1985). Gabapentin decreases monoamine release without affecting acetylcholine release in the brain. Arzeim.-Forsch/Drug Res., 35, 1347-1349.
39. SCHUMACHER, T., BECK, H., STEINHÄUSER, C., SCHRAMM, J. & ELGER, C.E. (1998). Effects of phenytoin, carbamazepine, and gabapentin on calcium channels in hippocampal granule cells from patients with temporal lobe epilepsy. Epilepsia, 39, 355-363.
40. SIESJÖ, B.K. & BENGTSSON, F. (1989). Calcium fluxes, calcium antagonists and calcium-related pathology in brain ischemia, hypoglycemia and spreading depression: a unifying hypothesis. J. Cereb. Blood Flow Metab., 9, 127-140.
41. STARKE, K., GÖTHERT, M. & KILBINGER, H. (1989). Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol. Rev., 69, 864-989.
42. STEFANI, A., SPADONI, F. & BERNARDI, G. (1998). Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology, 37, 83-91.
43. 3H]-gabapentin binding to a novel site in the rat brain: homogenate binding studies. Eur. J. Pharmacol., 244, 293-301.
44. SUSZKIW, O.B., MURAWSKY, M.M. & SHI, M. (1989). Further characterization of phasic calcium influx in rat cerebrocortical synaptosomes: Interferences regarding calcium channel type(s) in nerve endings. J. Neurosci., 52, 1260-1269.
45. TAREILUS, E., SCHOCH, J., ADAMS, M.E. & BREER, H. (1993). Analysis of rapid calcium signals in synaptosomes. Neurochem. Int., 23, 331-361.
46. TYMIANSKI, M. & TATOR, C.H. (1996). Normal and abnormal calcium homeostasis in neurons: a basis for the pathophysiology of traumatic and ischemic central nervous system injury. Neurosurgery, 38, 1176-1195.
47. VOLLMER, K.O. & VON HODENBERG, A. & KÖLLE, E.U. (1986). Pharmacokinetics and metabolism of gabapentin in rat, dog, and man. Arzeim.-Frosch./Drug Res., 36, 830-839.
48. WANG, M., OFFORD, J., OXENDER, D.L. & SU, T.Z. (1999). Structural requirement of the calcium-channel subunit alpha2delta for gabapentin binding. Biochem. J., 342, 313-320.